BioLife shareholders should vote FOR the merger proposal at the special meeting on October 5, 2026. If approved, the merger is expected to close in Q4 2026, and shares should trade near the implied merger consideration value until closing. Monitor for any competing proposals or regulatory delays.
Price Chart
Executive Summary
BioLife Solutions (BLFS) is seeking stockholder approval for its acquisition by Repligen Corporation (RGEN) in a cash-and-stock deal offering $11.25 cash plus 0.1442 RGEN shares per BLFS share. The BioLife board unanimously recommends voting FOR, with the special meeting scheduled for October 5, 2026. If approved, the merger is expected to close in Q4 2026, and BLFS stockholders will own approximately 11.1% of the combined company.
Key Financial Metrics
Key Facts
- Merger consideration: $11.25 cash + 0.1442 shares of Repligen common stock per BioLife share
- Implied value per BioLife share: $31.00 as of July 21, 2026 (pre-announcement) and $36.19 as of September 2, 2026
- BioLife stockholders will own approximately 11.1% of Repligen post-merger
- Special meeting: October 5, 2026; vote requires majority of outstanding shares
- Board unanimously recommends FOR (with Tony Hunt recused)
- Centerview Partners fairness opinion: consideration fair from a financial point of view
- Termination fee of $59 million payable by BioLife in certain circumstances
- Appraisal rights available under Delaware law
- Expected closing: Q4 2026, subject to stockholder approval, HSR clearance, and other conditions
Financial Impact
Per share consideration of $11.25 cash plus 0.1442 shares of Repligen common stock, implying a value of approximately $36.19 per BioLife share as of September 2, 2026.
Risk Factors
- Failure to obtain stockholder approval (requires majority of outstanding shares)
- Regulatory hurdles including HSR and foreign investment approvals
- Termination fee of $59 million if deal falls through under certain conditions
- Potential for appraisal rights litigation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001193125-26-383837 |
| Document: d112843ddefm14a.htm | 0001193125-26-383837 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | DEFM14A | $35.38 $36.39 | ▲ +2.85% | ▲ +3.97% | $37.53 (+6.06%) |
Jun 3, 2026 17w ago | 8-K | $27.25 $26.66 | ▼ −2.17% | ▲ +1.65% | $37.53 (+37.71%) |
Apr 28, 2026 22w ago | 10-K/A | $19.99 $21.75 | ▲ +8.80% | ▲ +5.69% | $37.53 (+87.72%) |
Mar 3, 2026 30w ago | Insider Cluster | $20.17 $18.67 | ▲ +7.44% | ▲ +6.96% | $37.53 (−86.04%) |
Mar 3, 2026 30w ago | Insider Cluster | $20.17 $18.67 | ▼ −7.44% | ▼ −6.96% | $37.53 (+86.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access